Latest period
$65.80M
YoY change
-9.5%
5Y CAGR
+11.8%
Peak year (2024)
$69.30M
Latest annual
$62.70M
Stock-Based Compensation history chart for Insulet (PODD) from 2004 to 2025
Latest: $62.70M
Stock-Based Compensation growth chart for Insulet (PODD) from 2004 to 2025
Latest: -9.5%
Stock-Based Compensation history table for Insulet (PODD) from 2004 to 2025
| 2025 | $62.70M | -9.5% | −$6.60M | ||
| 2024 | $69.30M | +43.5% | +$21.00M | ||
| 2023 | $48.30M | +18.1% | +$7.40M | ||
| 2022 | $40.90M | +18.9% | +$6.50M | ||
| 2021 | $34.40M | -4.2% | −$1.50M | ||
| 2020 | $35.90M | +25.1% | +$7.20M | ||
| 2019 | $28.70M | -23.5% | −$8.80M | ||
| 2018 | $37.50M | +17.6% | +$5.60M | ||
| 2017 | $31.90M | +35.1% | +$8.28M | ||
| 2016 | $23.62M | +23.1% | +$4.44M | ||
| 2015 | $19.18M | -14.8% | −$3.34M | ||
| 2014 | $22.52M | +77.6% | +$9.84M | ||
| 2013 | $12.68M | +27.9% | +$2.76M | ||
| 2012 | $9.92M | +28.3% | +$2.19M | ||
| 2011 | $7.73M | +52.7% | +$2.67M | ||
| 2010 | $5.06M | +20.5% | +$862.00K | ||
| 2009 | $4.20M | +24.8% | +$834.00K | ||
| 2008 | $3.37M | — | +$3.37M | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | $0.00 | ||
| 2005 | $0.00 | — | $0.00 | ||
| 2004 | $0.00 | — | — |
- 2025$62.70M-9.5%
- 2024$69.30M+43.5%
- 2023$48.30M+18.1%
- 2022$40.90M+18.9%
- 2021$34.40M-4.2%
- 2020$35.90M+25.1%
- 2019$28.70M-23.5%
- 2018$37.50M+17.6%
- 2017$31.90M+35.1%
- 2016$23.62M+23.1%
- 2015$19.18M-14.8%
- 2014$22.52M+77.6%
- 2013$12.68M+27.9%
- 2012$9.92M+28.3%
- 2011$7.73M+52.7%
- 2010$5.06M+20.5%
- 2009$4.20M+24.8%
- 2008$3.37M—
- 2007$0.00—
- 2006$0.00—
- 2005$0.00—
- 2004$0.00—
Stock-Based Compensation values are taken from Insulet's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Insulet (PODD)
Stock-Based Compensation for Insulet (PODD): headline value $65.80M · YoY -9.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Insulet (PODD) reported stock-based compensation of $62.70M – declined 9.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Insulet stock-based compensation compounded at +11.8% per year, with mixed annual results across the window.
2024 marks the peak stock-based compensation at $69.30M, with the historical low of $0.00 recorded in 2004.
Insulet Stock-Based Compensation by Year
Insulet Stock-Based Compensation 2025: $62.70M
Insulet stock-based compensation in 2025 was $62.70M, declined 9.5% below 2024.
Insulet Stock-Based Compensation 2024: $69.30M
2024's stock-based compensation for Insulet came in at $69.30M, surged 43.5% from 2023. This figure represents the highest annual value in the available history.
Insulet Stock-Based Compensation 2023: $48.30M
Insulet posted stock-based compensation of $48.30M in 2023, grew 18.1% from 2022.
Insulet Stock-Based Compensation 2022: $40.90M
In 2022, Insulet reported stock-based compensation of $40.90M, grew 18.9% from 2021.
Insulet Stock-Based Compensation 2021: $34.40M
Insulet stock-based compensation in 2021 was $34.40M.
See more financial history for Insulet (PODD).
Sector peers by Stock-Based Compensation
Healthcare peers of Insulet (PODD), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation